BRIEF

on MedMira, Inc. (CVE:MIR)

MedMira's Syphilis Test Receives FDA Breakthrough Device Designation

MedMira Inc., a company known for developing rapid diagnostic technologies, has received the U.S. FDA Breakthrough Device Designation for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test. This acknowledgement comes from the FDA's Center for Devices and Radiological Health, highlighting the device's potential to improve syphilis diagnosis, a significant public health challenge globally.

The test utilizes MedMira's Rapid Vertical Flow Technology, allowing simultaneous detection of treponemal and non-treponemal antibodies from a single blood sample. This contrasts with traditional methods requiring multiple procedures and infrastructure. The test may be particularly beneficial in areas with limited access to laboratory services.

The FDA's designation aims to accelerate the test's development and regulatory processes. However, it is not equivalent to FDA clearance for commercial use. MedMira sees this as an essential step in enhancing healthcare accessibility and hopes for further collaboration with the FDA.

R. H.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all MedMira, Inc. news